AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026

Loading news article.

AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026 | WAPE

AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026

Article summary

Related companies

Comments —